603148-36-3
Chemical Structure
Azeliragon
Synonym(s): TTP488; PF-04494700
- CAS No.: 603148-36-3
- Formula:C32H38ClN3O2
- Molecular Weight:532.12
IUPAC Name: 3-(4-(2-butyl-1-(4-(4-chlorophenoxy)phenyl)-1H-imidazol-4-yl)phenoxy)-N,N-diethylpropan-1-amine
InChIKey: KJNNWYBAOPXVJY-UHFFFAOYSA-N
SMILES: ClC1=CC=C(C=C1)OC2=CC=C(C=C2)N3C(CCCC)=NC(C(C=C4)=CC=C4OCCCN(CC)CC)=C3
Biological Activity: Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD)[1]. Azeliragon also can cross the blood-brain barrier (BBB)[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Azeliragon | 99.75% | Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Azeliragon (Standard) | ≥98% | Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.98
HY-50682AAzeliragon dihydrochloride -
Similarity Score 0.50
HY-178016H3R antagonist 8 -
Similarity Score 0.49
HY-146381SARS-CoV-2-IN-20 -
Similarity Score 0.49
HY-13946BML-277 -
Similarity Score 0.47
HY-175496Acid Ceramidase-IN-3 -
Similarity Score 0.47
HY-179474TSI-13-57 -
Similarity Score 0.47
HY-146062Antibacterial agent 101 -
Similarity Score 0.46
HY-111015AIRC-083927 -
Similarity Score 0.46
HY-139365mPGES1-IN-5 -
Explore the MedChemAI to find more analogs
References
- [1]. Burstein AH, et al. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clin Pharmacol Drug Dev. 2019 May;8(4):426-435. [Content Brief]
- [2]. Bongarzone S, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem. 2017 Sep 14;60(17):7213-7232. [Content Brief]
